RS55995B1 - Prevencija neželjenih efekata uzrokovanih cd3-specifičnim vezujućim domenima - Google Patents
Prevencija neželjenih efekata uzrokovanih cd3-specifičnim vezujućim domenimaInfo
- Publication number
- RS55995B1 RS55995B1 RS20170458A RSP20170458A RS55995B1 RS 55995 B1 RS55995 B1 RS 55995B1 RS 20170458 A RS20170458 A RS 20170458A RS P20170458 A RSP20170458 A RS P20170458A RS 55995 B1 RS55995 B1 RS 55995B1
- Authority
- RS
- Serbia
- Prior art keywords
- prevention
- specific binding
- adverse effects
- binding domains
- effects caused
- Prior art date
Links
- 230000002411 adverse Effects 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000009870 specific binding Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Developing Agents For Electrophotography (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41222910P | 2010-11-10 | 2010-11-10 | |
| PCT/EP2011/068862 WO2012062596A1 (en) | 2010-11-10 | 2011-10-27 | Prevention of adverse effects caused by cd3 specific binding domains |
| EP11788077.3A EP2637670B2 (en) | 2010-11-10 | 2011-10-27 | Prevention of adverse effects caused by cd3 specific binding domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RS55995B1 true RS55995B1 (sr) | 2017-09-29 |
| RS55995B2 RS55995B2 (sr) | 2024-04-30 |
Family
ID=45044532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20170458A RS55995B2 (sr) | 2010-11-10 | 2011-10-27 | Prevencija neželjenih efekata uzrokovanih cd3-specifičnim vezujućim domenima |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US10130638B2 (sr) |
| EP (3) | EP2637670B2 (sr) |
| JP (2) | JP6023717B2 (sr) |
| KR (1) | KR101891845B1 (sr) |
| CN (2) | CN103533943B (sr) |
| AU (3) | AU2011328393B2 (sr) |
| CA (1) | CA2816668C (sr) |
| CL (1) | CL2013001287A1 (sr) |
| CR (1) | CR20130278A (sr) |
| CY (1) | CY1118894T1 (sr) |
| DK (1) | DK2637670T4 (sr) |
| EA (1) | EA026075B1 (sr) |
| ES (2) | ES2627538T3 (sr) |
| FI (1) | FI2637670T4 (sr) |
| HR (1) | HRP20170814T4 (sr) |
| HU (1) | HUE032782T2 (sr) |
| IL (2) | IL226268B (sr) |
| LT (1) | LT2637670T (sr) |
| MA (1) | MA34726B1 (sr) |
| ME (1) | ME02722B (sr) |
| MY (1) | MY173177A (sr) |
| NZ (1) | NZ610034A (sr) |
| PL (1) | PL2637670T5 (sr) |
| PT (1) | PT2637670T (sr) |
| RS (1) | RS55995B2 (sr) |
| SG (2) | SG10201508789TA (sr) |
| SI (1) | SI2637670T2 (sr) |
| TN (1) | TN2013000250A1 (sr) |
| UA (1) | UA113397C2 (sr) |
| WO (1) | WO2012062596A1 (sr) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1874821T3 (pl) | 2005-04-26 | 2013-09-30 | Trion Pharma Gmbh | Kombinacja przeciwciał i glikokortykoidów do leczenia raka |
| KR101891845B1 (ko) | 2010-11-10 | 2018-08-24 | 암젠 리서치 (뮌헨) 게엠베하 | Cd3-특이적 결합 도메인에 의해 유발된 악영향의 예방 |
| ES2806142T3 (es) * | 2011-04-28 | 2021-02-16 | Amgen Res Munich Gmbh | Pauta posológica para administrar un anticuerpo biespecífico CD19xCD3 a pacientes en riesgo de posibles efectos adversos |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US10738132B2 (en) * | 2013-01-14 | 2020-08-11 | Xencor, Inc. | Heterodimeric proteins |
| JO3529B1 (ar) * | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
| CN105377889B (zh) * | 2013-03-15 | 2020-07-17 | Xencor股份有限公司 | 异二聚体蛋白 |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| EP3421495A3 (en) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| DK3736292T3 (da) | 2013-12-17 | 2024-07-22 | Genentech Inc | Anti-CD3-antistoffer og fremgangsmåder til anvendelse |
| BR112016022385A2 (pt) | 2014-03-28 | 2018-06-19 | Xencor, Inc | anticorpos específicos que se ligam a cd38 e cd3 |
| AR101846A1 (es) | 2014-09-12 | 2017-01-18 | Genentech Inc | Anticuerpos anti-cll-1 e inmunoconjugados |
| CN110894240B (zh) | 2014-11-26 | 2022-04-15 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| AR102918A1 (es) | 2014-12-05 | 2017-04-05 | Genentech Inc | Anticuerpos anti-cd79b y métodos de uso |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US10501545B2 (en) | 2015-06-16 | 2019-12-10 | Genentech, Inc. | Anti-CLL-1 antibodies and methods of use |
| AR105026A1 (es) | 2015-06-16 | 2017-08-30 | Genentech Inc | ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO |
| EP3322735A4 (en) | 2015-07-15 | 2019-03-13 | Zymeworks Inc. | BISPECIFIC ANTIGEN-BINDING CONSTRUCTS CONJUGATED TO A MEDICINAL PRODUCT |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| CN106810610A (zh) * | 2015-11-30 | 2017-06-09 | 中国科学院深圳先进技术研究院 | 抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用 |
| CN106810611A (zh) * | 2015-11-30 | 2017-06-09 | 中国科学院深圳先进技术研究院 | 抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用 |
| JP7058219B2 (ja) | 2015-12-07 | 2022-04-21 | ゼンコア インコーポレイテッド | Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体 |
| EA039859B1 (ru) * | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| SG11201806150RA (en) | 2016-02-03 | 2018-08-30 | Amgen Res Munich Gmbh | Psma and cd3 bispecific t cell engaging antibody constructs |
| CA3026151A1 (en) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| EP3475304B1 (en) | 2016-06-28 | 2022-03-23 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| PE20191034A1 (es) | 2016-10-14 | 2019-08-05 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15r y fragmentos de anticuerpo pd-1 |
| MX2019005438A (es) | 2016-11-15 | 2019-08-16 | Genentech Inc | Dosificacion para tratamiento con anticuerpos bispecificos anti-cd20 / anti-cd3. |
| JP7227131B2 (ja) * | 2016-12-03 | 2023-02-21 | ジュノー セラピューティクス インコーポレイテッド | Ｃａｒ－ｔ細胞の投薬を決定するための方法 |
| KR20180090600A (ko) | 2017-02-03 | 2018-08-13 | 주식회사 대유위니아 | 전기밥솥 |
| EP3409322A1 (en) * | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| CN111051534A (zh) * | 2017-08-30 | 2020-04-21 | 百时美施贵宝公司 | 监测体内施用糖皮质激素介导的药效学反应的方法 |
| WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| EP3706793A1 (en) | 2017-11-08 | 2020-09-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| JP2021506291A (ja) | 2017-12-19 | 2021-02-22 | ゼンコア インコーポレイテッド | 改変されたｉｌ−２ ｆｃ融合タンパク質 |
| AR115360A1 (es) | 2018-02-08 | 2021-01-13 | Genentech Inc | Moléculas de unión al antígeno y métodos de uso |
| CA3096052A1 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| CA3097741A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| US11524991B2 (en) | 2018-04-18 | 2022-12-13 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
| SG11202103192RA (en) | 2018-10-03 | 2021-04-29 | Xencor Inc | Il-12 heterodimeric fc-fusion proteins |
| JP2022523946A (ja) | 2019-03-01 | 2022-04-27 | ゼンコア インコーポレイテッド | Ｅｎｐｐ３およびｃｄ３に結合するヘテロ二量体抗体 |
| KR20230031981A (ko) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| RU2738802C1 (ru) * | 2019-08-21 | 2020-12-17 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула |
| TW202128767A (zh) | 2019-12-13 | 2021-08-01 | 美商建南德克公司 | 抗ly6g6d抗體及其使用方法 |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| MX2022015872A (es) | 2020-06-11 | 2023-05-16 | Provention Bio Inc | Metodos y composiciones para prevenir diabetes tipo 1. |
| JP2023538891A (ja) | 2020-08-19 | 2023-09-12 | ゼンコア インコーポレイテッド | 抗ｃｄ２８組成物 |
| AU2022232375A1 (en) | 2021-03-09 | 2023-09-21 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
| WO2023057650A1 (en) | 2021-10-10 | 2023-04-13 | Centre Hospitalier Universitaire Vaudois (Chuv) | A method for predicting side effects of drugs and vaccines |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
| NZ507381A (en) * | 1998-04-21 | 2003-12-19 | Micromet Ag | CD19xCD3 specific polypeptides and uses thereof |
| US20070224191A1 (en) † | 2002-12-05 | 2007-09-27 | Pdl Biopharma, Inc. | Methods of treatment of Ulcerative Colitis and Crohn's disease with anti-CD3 antibodies |
| AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| PL1874821T3 (pl) | 2005-04-26 | 2013-09-30 | Trion Pharma Gmbh | Kombinacja przeciwciał i glikokortykoidów do leczenia raka |
| CN101331151A (zh) | 2005-12-16 | 2008-12-24 | 麦克罗梅特股份公司 | 治疗肿瘤性疾病的方式和方法 |
| WO2007068354A1 (en) * | 2005-12-16 | 2007-06-21 | Micromet Ag | Means and methods for the treatment of tumorous diseases |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| CA2683370C (en) | 2007-04-03 | 2022-12-13 | Micromet Ag | Cross-species-specific binding domain |
| PL2155788T3 (pl) | 2007-04-03 | 2013-02-28 | Amgen Res Munich Gmbh | Swoiste międzygatunkowe bispecyficzne czynniki wiążące |
| JP5490714B2 (ja) | 2007-11-28 | 2014-05-14 | メディミューン，エルエルシー | タンパク質製剤 |
| ME03480B (me) * | 2008-11-07 | 2020-01-20 | Amgen Res Munich Gmbh | Tretiranje akutne limfoblastne leukemije |
| DK2493503T4 (da) * | 2009-10-27 | 2021-04-12 | Amgen Res Munich Gmbh | Doseringsplan for administrering af et cd19xcd3-bispecifikt antistof |
| CN105251003B (zh) * | 2010-10-27 | 2019-08-02 | 安进研发（慕尼黑）股份有限公司 | 用于治疗dlbcl的装置和方法 |
| KR101891845B1 (ko) | 2010-11-10 | 2018-08-24 | 암젠 리서치 (뮌헨) 게엠베하 | Cd3-특이적 결합 도메인에 의해 유발된 악영향의 예방 |
-
2011
- 2011-10-27 KR KR1020137014669A patent/KR101891845B1/ko active IP Right Grant
- 2011-10-27 CN CN201180064622.5A patent/CN103533943B/zh active Active
- 2011-10-27 AU AU2011328393A patent/AU2011328393B2/en active Active
- 2011-10-27 RS RS20170458A patent/RS55995B2/sr unknown
- 2011-10-27 PL PL11788077.3T patent/PL2637670T5/pl unknown
- 2011-10-27 HR HRP20170814TT patent/HRP20170814T4/hr unknown
- 2011-10-27 SG SG10201508789TA patent/SG10201508789TA/en unknown
- 2011-10-27 FI FIEP11788077.3T patent/FI2637670T4/fi active
- 2011-10-27 EP EP11788077.3A patent/EP2637670B2/en active Active
- 2011-10-27 LT LTEP11788077.3T patent/LT2637670T/lt unknown
- 2011-10-27 US US13/884,497 patent/US10130638B2/en active Active
- 2011-10-27 ES ES11788077.3T patent/ES2627538T3/es active Active
- 2011-10-27 EP EP17159560.6A patent/EP3228315B1/en active Active
- 2011-10-27 PT PT117880773T patent/PT2637670T/pt unknown
- 2011-10-27 ME MEP-2017-104A patent/ME02722B/me unknown
- 2011-10-27 CN CN201810044039.1A patent/CN108403702A/zh active Pending
- 2011-10-27 CA CA2816668A patent/CA2816668C/en active Active
- 2011-10-27 ES ES17159560T patent/ES2842937T3/es active Active
- 2011-10-27 EA EA201390621A patent/EA026075B1/ru not_active IP Right Cessation
- 2011-10-27 NZ NZ610034A patent/NZ610034A/en unknown
- 2011-10-27 UA UAA201307130A patent/UA113397C2/uk unknown
- 2011-10-27 SG SG2013034731A patent/SG190174A1/en unknown
- 2011-10-27 HU HUE11788077A patent/HUE032782T2/en unknown
- 2011-10-27 SI SI201131196T patent/SI2637670T2/sl unknown
- 2011-10-27 DK DK11788077.3T patent/DK2637670T4/da active
- 2011-10-27 MY MYPI2013001611A patent/MY173177A/en unknown
- 2011-10-27 EP EP20209362.1A patent/EP3831386A1/en active Pending
- 2011-10-27 JP JP2013538125A patent/JP6023717B2/ja active Active
- 2011-10-27 WO PCT/EP2011/068862 patent/WO2012062596A1/en active Application Filing
-
2013
- 2013-05-09 IL IL226268A patent/IL226268B/en active IP Right Grant
- 2013-05-09 CL CL2013001287A patent/CL2013001287A1/es unknown
- 2013-06-10 MA MA35999A patent/MA34726B1/fr unknown
- 2013-06-10 CR CR20130278A patent/CR20130278A/es unknown
- 2013-06-10 TN TNP2013000250A patent/TN2013000250A1/fr unknown
-
2016
- 2016-07-06 JP JP2016133918A patent/JP6189491B2/ja active Active
-
2017
- 2017-03-29 AU AU2017202079A patent/AU2017202079B2/en active Active
- 2017-05-08 CY CY20171100491T patent/CY1118894T1/el unknown
-
2018
- 2018-01-25 IL IL257164A patent/IL257164B/en active IP Right Grant
- 2018-02-07 AU AU2018200915A patent/AU2018200915B2/en active Active
- 2018-10-11 US US16/157,985 patent/US11633408B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201508789TA (en) | Prevention of adverse effects caused by cd3 specific binding domains | |
| HK1247938A1 (zh) | 結合分子的生成 | |
| DK2782942T3 (en) | Modified binder compositions | |
| AP4082A (en) | Anti-cd40 antibodies | |
| EP2569429A4 (en) | COMPOSITIONS AND METHOD OF METABOLIC MODULATION | |
| EP2717876A4 (en) | METHOD FOR INHIBITING MUSCLE ATROPHY | |
| IL227656A0 (en) | Immunoglobulin site engineering | |
| EP2636736A4 (en) | NOVEL ANTI-DR5 ANTIBODY | |
| EP2553457A4 (en) | METHOD FOR DETERMINING A BOND FLUID METHOMETRY | |
| GB201005275D0 (en) | Agents to prevent binding | |
| IL221110A0 (en) | Antibodies that inhibit metalloproteins | |
| HU1000306D0 (en) | Magnetic stopper for baths | |
| PL392380A1 (pl) | Zestaw do realizacji przesyłu informacji |